3月3日，凯莱英跌2.05%，截至发稿，报92.50元/股，成交4.65亿元，换手率1.59%，总市值333.81亿 元。凯莱英股价已经连续4天下跌，区间累计跌幅7.07%。 摩根安通回报混合A（004361）成立日期2017年4月26日，最新规模1361.17万。今年以来收益2.8%，同 类排名5873/8892；近一年收益13.85%，同类排名5668/8141；成立以来收益60.69%。 摩根安通回报混合A（004361）基金经理为周梦婕。 从基金十大重仓股角度 数据显示，摩根基金旗下1只基金重仓凯莱英。摩根安通回报混合A（004361）四季度持有股数3500 股，占基金净值比例为1.24%，位居第五大重仓股。根据测算，今日浮亏损失约6790元。连续4天下跌 期间浮亏损失2.46万元。 截至发稿，周梦婕累计任职时间6年337天，现任基金资产总规模140.14亿元，任职期间最佳基金回报 37.22%， 任职期间最差基金回报1.71%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本 文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问 ...

Group 1 - The CXO sector experienced a notable rebound in early 2026, primarily driven by domestic demand-focused CRO and experimental service companies, while leading CDMO companies with significant global exposure underperformed [2][25] - The current market activity reflects a short-term rebound rather than a comprehensive recovery of the CXO industry, with investors favoring easily confirmable segments [2][25] Group 2 - After a low in 2024, domestic innovative drug financing has improved, with policy expectations and order stability more evident in companies focused on domestic demand, while external demand CDMOs face a more complex pricing environment [4][27] - Despite overall industry sentiment improving, the market remains cautious towards CDMOs, which are seen as having the most certain fundamental recovery and highest order visibility [4][27] Group 3 - WuXi AppTec's 2025 performance forecast indicates a projected revenue of approximately 45.46 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 19.15 billion RMB, reflecting a significant growth of 102.65% [6][30] - The company's revenue guidance was adjusted upward multiple times throughout the year, indicating a continuous improvement in order conversion, project advancement, and capacity utilization [6][29] Group 4 - Market sentiment towards WuXi AppTec is complex, with a significant portion of profit growth attributed to non-recurring gains from asset disposals, leading to a cautious market outlook despite strong operational performance [7][30] - The market's valuation reflects skepticism not about 2025 performance but about the sustainability of growth beyond 2027 [7][30] Group 5 - Concerns regarding the future growth of TIDES and geopolitical risks are central to market pricing, indicating a focus on long-term growth potential rather than immediate performance [9][32] - The demand for TIDES products remains strong, with supply chain share increasing, suggesting that the challenges are more about supply capacity than demand saturation [11][34] Group 6 - WuXi AppTec's growth is characterized by a platform-based expansion rather than reliance on a single segment, with significant performance in small molecule D&M business [15][38] - The company has improved operational efficiency and capacity utilization without significant capital investment, enhancing its competitive position in the global pharmaceutical outsourcing industry [17][40] Group 7 - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand area, emphasizing the importance of time in meeting customer needs [19][41] - This acquisition reflects a broader trend of consolidation in the industry, where leading companies are increasingly focused on embedding themselves deeper into the global innovative drug supply chain [21][43] Group 8 - The current rebound in the CXO sector appears to be driven by sentiment and expectations rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [22][44] - The ongoing structural changes in the industry suggest that companies that have successfully adjusted their order and capability structures may see their value reassessed in the future [22][45]

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Summary by Category - **Share Reduction** - Morgan Stanley sold 798,119 shares of WuXi AppTec [1] - The sale price was HKD 109.1481 per share [1] - The total amount from the sale was approximately HKD 87.1132 million [1] - **Current Holdings** - After the reduction, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million [1] - The new ownership percentage is 6.90% [1]

Core Viewpoint - WuXi AppTec focuses on its unique CRDMO business model to efficiently serve global clients and benefit patients worldwide [1] Group 1 - The company emphasizes the importance of its CRDMO business model in generating industry insights quickly [1] - The CRDMO model allows the company to respond promptly to new molecular demands from clients [1] - The commitment to the CRDMO business model is seen as a strategy to ensure the company's long-term development [1]

Group 1: Commercial Aerospace - The Chinese commercial aerospace sector is entering a new phase aimed at large-scale launches and commercial closed-loop systems, with significant breakthroughs expected in rocket capacity over the next 3 to 5 years [1] - By 2025, China's commercial aerospace is projected to complete 50 launches, accounting for 54% of total space launches, with 25 commercial rockets launched and 311 commercial satellites in orbit, representing 84% of total satellites [1] - The capital market for commercial aerospace companies is accelerating, with several leading firms preparing for IPOs, including Blue Arrow Aerospace and Zhongke Aerospace [1] Group 2: Public Fund Performance - The latest public fund reports reveal that the top ten holdings include companies like Zhongji Xuchuang, Ningde Times, and Tencent, with notable increases in holdings for companies like Zhongji Xuchuang, which saw an increase of 22.602 billion yuan [2] - The automotive industry is facing cost pressures due to rising prices of memory chips and metals, impacting supply chain dynamics and competition [2] Group 3: Biopharmaceutical Industry - Over 50 biopharmaceutical companies have disclosed their 2025 performance forecasts, with nearly 50% showing positive expectations, particularly in the CXO sector, where WuXi AppTec anticipates a revenue increase of approximately 15.84% [3] - The biopharmaceutical industry is expected to enter a new phase of high-quality development as structural reforms and supportive policies continue to evolve [3] Group 4: Fundraising and Market Trends - The public fund market has seen a resurgence, with several equity funds raising over 7 billion yuan, indicating a positive trend in active equity fund performance [4] - The Shanghai Suiruan Technology Co., Ltd. has received approval for its IPO, aiming to raise 6 billion yuan for product development and business expansion [5] Group 5: Aluminum Market - The aluminum market has shown strong performance, with prices rising over 12% since mid-December 2025, supported by favorable macroeconomic conditions and demand for aluminum in various applications [6] - The copper-aluminum price ratio exceeding 4 suggests a potential shift towards aluminum in sectors like air conditioning, indicating new demand growth [6] Group 6: Banking Sector - Five listed banks have reported a year-on-year increase in net profit for 2025, with improvements in non-performing loan ratios for three banks [9] - The banking sector is expected to maintain stable performance, supported by improved funding costs and a potential stabilization of net interest margins [9] Group 7: Chemical Industry - The chemical industry is experiencing positive performance, with over 60% of companies reporting improved earnings, driven by rising prices of certain chemical products [10] - The DOP market is expected to maintain upward momentum due to strong raw material prices and limited supply, indicating a stable support for pricing [10]

Core Viewpoint - JPMorgan Chase has reduced its stake in WuXi AppTec (603259) by approximately 2.5178 million shares at a price of around HKD 119.32 per share, totaling about HKD 300 million, resulting in a new holding of approximately 33.644 million shares, representing 6.59% of the company [1][2]. Group 1 - On January 14, JPMorgan sold 2,517,805 shares of WuXi AppTec at an average price of HKD 119.3249 per share [2]. - Following the sale, JPMorgan's remaining shares in WuXi AppTec amount to approximately 33,644,022 shares, with a holding percentage of 6.59% [1][2]. - The total cash generated from this reduction in stake is approximately HKD 300 million [2].

Group 1 - The core point of the news is the acquisition of Easton Pharmaceuticals by WuXi AppTec, which aims to strengthen its position in the ADC (Antibody-Drug Conjugate) sector by acquiring a CDMO (Contract Development and Manufacturing Organization) company at a significant premium of approximately 99% over the market price [1][2] - The acquisition is valued at around HKD 3.1 billion, with WuXi AppTec offering HKD 4 per share for Easton Pharmaceuticals, which has a market capitalization of HKD 31.68 billion post-announcement [1][2] - Following the acquisition announcement, Easton Pharmaceuticals' stock surged by 64%, while WuXi AppTec's stock initially rose but later fell by 3.04% [1] Group 2 - The ADC market has seen substantial growth, with a compound annual growth rate (CAGR) of 38.6%, increasing from USD 2 billion in 2018 to USD 10.4 billion in 2023, and is projected to continue expanding with 21 ADC drugs expected to be approved by the end of 2025 [4] - WuXi AppTec, established in May 2021, is uniquely positioned in the industry as it holds capabilities in small molecule toxins, linkers, and antibody biologics, making it a comprehensive player in the ADC space [4][5] - Easton Pharmaceuticals, originally a biotech company focused on ADC drug development, has shifted its strategy to become a full-fledged ADC CDMO after terminating its TAA013 project due to competitive pressures from similar products [5][6] Group 3 - Easton Pharmaceuticals has faced challenges in its revenue contributions from its CDMO business, with product sales accounting for 80% of its revenue, and a decline in both product sales and CDMO/CMO business revenue reported for the first half of 2025 [6] - WuXi AppTec has been actively expanding its production capacity, with a global dual-plant strategy and a recent completion of a USD 350 million refinancing to support this expansion [7][9] - The acquisition is seen as a potential turning point for the industry, reflecting a trend of consolidation and capacity expansion among key players in the ADC market [9]

Group 1 - Kailaiying's stock price increased by 1.32% to 105.87 CNY per share, with a trading volume of 977 million CNY and a turnover rate of 2.88%, resulting in a total market capitalization of 38.176 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 5.49% during this period [1] - Kailaiying Pharmaceutical Group, established on October 7, 1998, and listed on November 18, 2016, primarily provides CMO pharmaceutical outsourcing services, with revenue composition of 76.19% from small molecule CDMO solutions, 23.71% from emerging services, and 0.10% from other sources [1] Group 2 - Newwo Fund has a significant holding in Kailaiying, with its Newwo Domestic Demand Growth Mixed A Fund (012143) reducing its position by 200 shares to hold 4,800 shares, representing 4.99% of the fund's net value, ranking as the ninth largest holding [2] - The fund has realized a floating profit of approximately 6,624 CNY today, accumulating a floating profit of 26,400 CNY during the three-day increase [2] - The Newwo Domestic Demand Growth Mixed A Fund was established on September 9, 2021, with a latest scale of 8.5055 million CNY, achieving a year-to-date return of 10.7% and a one-year return of 40.04% [2]

Core Viewpoint - Morgan Stanley's research report indicates that WuXi AppTec's revenue is expected to increase by 15.8% year-on-year to 45.5 billion yuan in 2025, with profits rising by 102.7% to 19.2 billion yuan, and adjusted non-IFRS profits increasing by 41.3% to 15 billion yuan [1] Revenue and Profit Growth - Revenue from continuing operations is projected to grow by 21.4% year-on-year, surpassing management's expectations of 17% to 18% [1] - The growth is primarily driven by the later-stage R&D and commercialization contracts in the chemical business, as well as strong performance in the TIDES business [1] One-time Gains - The company confirmed two significant one-time gains during the year, including approximately 4.2 billion yuan from the partial divestment of WuXi AppTec's equity and about 1.4 billion yuan from the sale of its testing business [1] Investment Outlook - Morgan Stanley continues to list WuXi AppTec as a preferred stock for 2026, setting a target price of 130 yuan for its A-shares and maintaining an "overweight" rating [1] - Future catalysts include updated business outlooks from brokerage meetings and a potential easing of geopolitical headwinds [1]

Group 1 - The core viewpoint of the article is that WuXi AppTec (603259.SH/02359) has announced a significant increase in its revenue forecast for the year 2025, projecting approximately 45.456 billion yuan, marking a historical high [1] - The company has raised its annual performance guidance for the second time in the third quarter, indicating a strong focus on customer demand, business model, and management execution certainty [1] - WuXi AppTec expects its continuous operating business to return to double-digit growth, with an adjusted growth rate of 17-18%, and overall revenue revised to 43.5-44 billion yuan [1] Group 2 - In terms of profitability, key indicators under three metrics are expected to grow at a rate higher than revenue, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit attributable to shareholders after deducting non-recurring gains and losses projected to increase by approximately 41.33%, 102.65%, and 32.56% year-on-year, respectively [1]